| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/1078-0432.CCR-13-2702 |
| P698 | PubMed publication ID | 24647569 |
| P50 | author | Kurt A Schalper | Q94671899 |
| P2093 | author name string | David L Rimm | |
| Lajos Pusztai | |||
| Jason Brown | |||
| Vamsidhar Velcheti | |||
| Hallie Wimberly | |||
| Daniel Carvajal | |||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2773-2782 | |
| P577 | publication date | 2014-03-19 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas | |
| P478 | volume | 20 |
| Q37470361 | An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers |
| Q35182037 | Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). |
| Q36539682 | Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells |
| Q57937919 | Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival |
| Q38642012 | Association between PD-L1 Expression on Tumour-Infiltrating Lymphocytes and Overall Survival in Patients with Gastric Cancer |
| Q46067261 | Association between PD-L1 expression combined with tumor-infiltrating lymphocytes and the prognosis of patients with advanced hypopharyngeal squamous cell carcinoma |
| Q60045778 | Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer |
| Q37474092 | Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors |
| Q60951859 | Automated Tumour Recognition and Digital Pathology Scoring Unravels New Role for PD-L1 in Predicting Good Outcome in ER-/HER2+ Breast Cancer |
| Q48141292 | Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study |
| Q50886634 | BIN1 reverses PD-L1-mediated immune escape by inactivating the c-MYC and EGFR/MAPK signaling pathways in non-small cell lung cancer. |
| Q39370768 | Biological Subtypes of Triple-Negative Breast Cancer |
| Q27311085 | Biological network-driven gene selection identifies a stromal immune module as a key determinant of triple-negative breast carcinoma prognosis |
| Q39181810 | Biomarkers and Immunotherapeutic Targets in Glioblastoma |
| Q33814411 | Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia |
| Q38584383 | Breast cancer and immunology: biomarker and therapeutic developments |
| Q53753190 | CD103+ Cell Growth Factor Flt3L Enhances the Efficacy of Immune Checkpoint Blockades in Murine Glioblastoma Model. |
| Q60044419 | CD68, CD163, and matrix metalloproteinase 9 (MMP-9) co-localization in breast tumor microenvironment predicts survival differently in ER-positive and -negative cancers |
| Q35812429 | Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites |
| Q26745442 | Checkpoint Inhibitors and Their Application in Breast Cancer |
| Q38825945 | Clinical Implementation of Novel Targeted Therapeutics in Advanced Breast Cancer |
| Q89634339 | Clinical Relevance of Immune Checkpoints on Circulating Tumor Cells in Breast Cancer |
| Q38669465 | Clinical relevance of host immunity in breast cancer: from TILs to the clinic |
| Q33671093 | Clinical significance of T cell clonality and expression levels of immune-related genes in endometrial cancer |
| Q64116914 | Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas |
| Q28070214 | Clinical significance of tumor-infiltrating lymphocytes in breast cancer |
| Q42371619 | Clinicopathologic implications of the miR-197/PD-L1 axis in oral squamous cell carcinoma |
| Q42682646 | Clinicopathological and prognostic significance of programmed death ligand-1 expression in breast cancer: a meta-analysis. |
| Q48551091 | Combined drug therapeutic strategies for the effective treatment of Triple Negative Breast Cancer |
| Q41708934 | Combined prognostic effect of PD-L1 expression and immunoscore in microsatellite-unstable advanced gastric cancers |
| Q39308620 | Concordance of immune checkpoints within tumor immune contexture and their prognostic significance in gastric cancer. |
| Q26798074 | Current Issues and Clinical Evidence in Tumor-Infiltrating Lymphocytes in Breast Cancer |
| Q42644167 | DNA methylation-based immune response signature improves patient diagnosis in multiple cancers |
| Q58698521 | Diagnostic value of PD-1 mRNA expression combined with breast ultrasound in breast cancer patients |
| Q41924371 | Differentiated tumor immune microenvironment of Epstein-Barr virus-associated and negative gastric cancer: implication in prognosis and immunotherapy. |
| Q90619845 | Druggable Molecular Targets for the Treatment of Triple Negative Breast Cancer |
| Q41291930 | Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance. |
| Q55011828 | Effective screening of T cells recognizing neoantigens and construction of T-cell receptor-engineered T cells. |
| Q40208127 | Elevated T cell activation score is associated with improved survival of breast cancer. |
| Q26751029 | Epstein-Barr Virus-Associated Gastric Carcinoma and Specific Features of the Accompanying Immune Response |
| Q42378536 | Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8+ lymphocytes in primary sarcomas is subtype dependent. |
| Q95261294 | Expression and prognostic value of PD-L1 in non-schistosoma-associated urinary bladder squamous cell carcinoma |
| Q92724550 | Expression of PD-L1 Attenuates the Positive Impacts of High-level Tumor-infiltrating Lymphocytes on Prognosis of Triple-negative Breast Cancer |
| Q36994508 | Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies. |
| Q50099167 | Expression of Programmed Death Ligand 1 (PD-L1) in Posttreatment Primary Inflammatory Breast Cancers and Clinical Implications. |
| Q37316596 | Expression of Programmed Death Receptor Ligand 1 with High Tumor-Infiltrating Lymphocytes Is Associated with Better Prognosis in Breast Cancer |
| Q34270064 | Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer |
| Q39757066 | Fully Automated RNAscope In Situ Hybridization Assays for Formalin-Fixed Paraffin-Embedded Cells and Tissues |
| Q36665328 | Glucagon-Like Peptide-1 Receptor Expression in Normal and Neoplastic Human Pancreatic Tissues |
| Q47113036 | Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer |
| Q47125869 | High PD-L1 Expression Is Closely Associated With Tumor-Infiltrating Lymphocytes and Leads to Good Clinical Outcomes in Chinese Triple Negative Breast Cancer Patients |
| Q33566790 | High PD-L1 expression is associated with stage IV disease and poorer overall survival in 186 cases of small cell lung cancers |
| Q36545353 | High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer |
| Q91826286 | High-resolution imaging mass spectrometry combined with transcriptomic analysis identified a link between fatty acid composition of phosphatidylinositols and the immune checkpoint pathway at the primary tumour site of breast cancer |
| Q37316603 | Histomorphological Factors Predicting the Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer |
| Q92646650 | Identification of CTRP1 as a Prognostic Biomarker and Oncogene in Human Glioblastoma |
| Q47109363 | Immune Checkpoint Molecules on Tumor-Infiltrating Lymphocytes and Their Association with Tertiary Lymphoid Structures in Human Breast Cancer. |
| Q38823649 | Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication |
| Q36108008 | Immune profiling in human breast cancer using high-sensitivity detection and analysis techniques |
| Q52587066 | Immunotherapy for Breast Cancer: Current and Future Strategies. |
| Q44668850 | Immunotherapy for Breast Cancer: What Are We Missing? |
| Q38629357 | Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1. |
| Q41810793 | Impact of the Tumor Microenvironment on Tumor-Infiltrating Lymphocytes: Focus on Breast Cancer |
| Q47592007 | Implications of the tumor immune microenvironment for staging and therapeutics |
| Q35741539 | Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma |
| Q37702705 | Independent prognostic role of PD-L1expression in patients with esophageal squamous cell carcinoma |
| Q37650062 | Induction of PD-L1 expression by epidermal growth factor receptor-mediated signaling in esophageal squamous cell carcinoma |
| Q64103583 | Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer |
| Q40694190 | Intratumoral expression of programmed death ligand 1 (PD-L1) in patients with clear cell renal cell carcinoma (ccRCC). |
| Q26827104 | Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma |
| Q43115794 | Is immune checkpoint modulation a potential therapeutic option in triple negative breast cancer? |
| Q64097102 | Local and systemic delivery of mRNA encoding survivin-T34A by lipoplex for efficient colon cancer gene therapy |
| Q36553576 | Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. |
| Q34522172 | Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy |
| Q35009369 | Modelling the spatial heterogeneity and molecular correlates of lymphocytic infiltration in triple-negative breast cancer. |
| Q35973378 | Monocyte and interferon based therapy for the treatment of ovarian cancer |
| Q38601420 | Natural and therapy-induced immunosurveillance in breast cancer |
| Q38972343 | Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies. |
| Q42690881 | Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer |
| Q36047422 | Objective measurement and clinical significance of TILs in non-small cell lung cancer |
| Q27853205 | PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups |
| Q38754407 | PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer |
| Q39393005 | PD-1 and cancer: molecular mechanisms and polymorphisms. |
| Q41612447 | PD-1 mRNA expression in peripheral blood cells and its modulation characteristics in cancer patients |
| Q37708899 | PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes. |
| Q36652112 | PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. |
| Q34454922 | PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer |
| Q36882550 | PD-L1 Expression Is Associated with Tumor FOXP3(+) Regulatory T-Cell Infiltration of Breast Cancer and Poor Prognosis of Patient |
| Q55090803 | PD-L1 Expression Predicts a Distinct Prognosis in Krukenberg Tumor with Corresponding Origins. |
| Q55554951 | PD-L1 Expression and CD8+ T Cell Infiltration Predict a Favorable Prognosis in Advanced Gastric Cancer. |
| Q89947329 | PD-L1 Expression and Tumor-infiltrating Lymphocytes in Breast Cancer: Clinicopathological Analysis in Women Younger than 40 Years Old |
| Q97525213 | PD-L1 Expression in Glioblastoma, the Clinical and Prognostic Significance: A Systematic Literature Review and Meta-Analysis |
| Q48128973 | PD-L1 Expression in TNBC: A Predictive Biomarker of Response to Neoadjuvant Chemotherapy? |
| Q41553643 | PD-L1 and c-MET expression and survival in patients with small cell lung cancer |
| Q41612935 | PD-L1 and intratumoral immune response in breast cancer |
| Q37026725 | PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker |
| Q38668389 | PD-L1 expression and the immune microenvironment in primary invasive lobular carcinomas of the breast |
| Q39036924 | PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients |
| Q42096460 | PD-L1 expression and tumor-infiltrating lymphocytes: Revisiting the antitumor immune response potential in breast cancer |
| Q26738361 | PD-L1 expression in human cancers and its association with clinical outcomes |
| Q49365645 | PD-L1 expression in malignant salivary gland tumors |
| Q62888577 | PD-L1 expression is an independent predictor of favorable outcome in patients with localized esophageal adenocarcinoma |
| Q47912397 | PD-L1 in immune-escape of breast and prostate cancers: from biology to therapy |
| Q36903206 | PD-L1 polymorphism can predict clinical outcomes of non-small cell lung cancer patients treated with first-line paclitaxel-cisplatin chemotherapy |
| Q41035618 | PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes |
| Q50035044 | PD1 protein expression in tumor infiltrated lymphocytes rather than PDL1 in tumor cells predicts survival in triple-negative breast cancer. |
| Q35955369 | PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy |
| Q52682430 | PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas. |
| Q35798839 | PDL1 expression is an independent prognostic factor in localized GIST. |
| Q38393045 | Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. |
| Q40163779 | Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial |
| Q99581556 | Peritumoral immune infiltrates in primary tumours are not associated with the presence of axillary lymph node metastasis in breast cancer: a retrospective cohort study |
| Q38778546 | Pharmacogenetic Predictors of Response |
| Q49214132 | Posttranscriptional Control of PD-L1 Expression by 17β-Estradiol via PI3K/Akt Signaling Pathway in ERα-Positive Cancer Cell Lines |
| Q35934137 | Poxvirus-Based Active Immunotherapy with PD-1 and LAG-3 Dual Immune Checkpoint Inhibition Overcomes Compensatory Immune Regulation, Yielding Complete Tumor Regression in Mice |
| Q36637292 | Predictive Value of Neutrophil/Lymphocyte Ratio for Efficacy of Preoperative Chemotherapy in Triple-Negative Breast Cancer |
| Q92336457 | Predictive and prognostic value of PDL1 protein expression in breast cancer patients in neoadjuvant setting |
| Q37611683 | Predictive factors of the tumor immunological microenvironment for long-term follow-up in early stage breast cancer |
| Q93338919 | Product review: avelumab, an anti-PD-L1 antibody |
| Q36915205 | Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer |
| Q38898344 | Prognostic Role of Programmed Death Ligand-1 Expression in Breast Cancer: A Systematic Review and Meta-Analysis |
| Q42504152 | Prognostic Value of PD-L1 in Breast Cancer: A Meta-Analysis |
| Q36030084 | Prognostic and Clinicopathological Value of Programmed Death Ligand-1 in Breast Cancer: A Meta-Analysis |
| Q35741710 | Prognostic and predictive value of PDL1 expression in breast cancer |
| Q37199510 | Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer |
| Q27853285 | Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma |
| Q36072022 | Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma. |
| Q37327597 | Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma |
| Q38888197 | Prognostic significance of tumour infiltrating B lymphocytes in breast ductal carcinoma in situ. |
| Q55416061 | Prognostic value of PD-L1 in esophageal squamous cell carcinoma: a meta-analysis. |
| Q37687595 | Prognostic value of PDL1 expression in pancreatic cancer |
| Q55405564 | Prognostic values of the mRNA expression of natural killer receptor ligands and their association with clinicopathological features in breast cancer patients. |
| Q47099687 | Programmed Death Ligand 1 (PD-L1) Expression in Primary Angiosarcoma |
| Q37691082 | Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients |
| Q42365288 | Programmed cell death-ligand 1 expression and immunoscore in stage II and III non-small cell lung cancer patients receiving adjuvant chemotherapy |
| Q37706604 | Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability |
| Q37222152 | Programmed death ligand 1 as an indicator of pre-existing adaptive immune responses in human hepatocellular carcinoma |
| Q40296843 | Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome. |
| Q41718196 | Programmed death-ligand 1 (PD-L1) expression in tumour cell and tumour infiltrating lymphocytes of HER2-positive breast cancer and its prognostic value |
| Q37035423 | Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma |
| Q47094138 | Programmed death-ligand 1 expression correlates with diminished CD8+ T cell infiltration and predicts poor prognosis in anal squamous cell carcinoma patients |
| Q89961623 | Programmed death-ligand 1 gene expression is a prognostic marker in early breast cancer and provides additional prognostic value to 21-gene and 70-gene signatures in estrogen receptor-positive disease |
| Q33607407 | Programmed death-ligand 1 is prognostic factor in esophageal squamous cell carcinoma and is associated with epidermal growth factor receptor. |
| Q37457628 | Programmed death-ligand-1 expression in advanced gastric cancer detected with RNA in situ hybridization and its clinical significance |
| Q35251561 | Quantitative measurement of cancer tissue biomarkers in the lab and in the clinic |
| Q47102080 | RNAscope in situ hybridization confirms mRNA integrity in formalin-fixed, paraffin-embedded cancer tissue samples |
| Q90115374 | Reactive versus Constitutive: Reconcile the Controversial Results about the Prognostic Value of PD-L1 Expression in cancer |
| Q28067217 | Recent advances in understanding antitumor immunity |
| Q50042048 | Regulation of Programmed Death Ligand 1 (PD-L1) Expression in Breast Cancer Cell Lines In Vitro and in Immunodeficient and Humanized Tumor Mice |
| Q26795598 | Relevance of tumor-infiltrating lymphocytes in breast cancer |
| Q49549096 | Role of immune-checkpoint inhibitors in lung cancer |
| Q64238536 | Role of programmed cell death ligand-1 expression on prognostic and overall survival of breast cancer: A systematic review and meta-analysis |
| Q55088555 | Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case. |
| Q92129128 | Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy |
| Q92487389 | Significance of PD-L1 expression in carbon-ion radiotherapy for uterine cervical adeno/adenosquamous carcinoma |
| Q38741582 | Subtype-specific prognostic impact of different immune signatures in node-negative breast cancer. |
| Q89497074 | T cell immunoglobulin and mucin-domain containing-3 in non-small cell lung cancer |
| Q96133002 | The Association Between Immune Characteristic and Clinical Pathology in Chinese Patients with Adenocarcinoma of Esophagogastric Junction |
| Q64893007 | The BRCA1 Methylation and PD-L1 Expression in Sporadic Ovarian Cancer. |
| Q90290730 | The Clinical and Biomarker Association of Programmed Death Ligand 1 and its Spatial Heterogeneous Expression in Colorectal Cancer |
| Q40436041 | The PD1/PDL1 axis, a promising therapeutic target in aggressive breast cancers |
| Q64087718 | The Prognostic and Clinicopathological Roles of PD-L1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis |
| Q26797478 | The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients |
| Q37716582 | The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer |
| Q61772022 | The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome |
| Q39130461 | The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. |
| Q33834968 | The immune microenvironment of breast ductal carcinoma in situ |
| Q49787569 | The presence of PD-1 positive tumor infiltrating lymphocytes in triple negative breast cancers is associated with a favorable outcome of disease |
| Q64276549 | The prognostic significance of PD-L1 and PD-1 expression in patients with nasopharyngeal carcinoma: a systematic review and meta-analysis |
| Q90590018 | The prognostic significance of immune microenvironment in breast ductal carcinoma in situ |
| Q53079838 | The role of programmed death ligand-1 and tumor-infiltrating lymphocytes in breast cancer overexpressing HER2 gene. |
| Q52771838 | The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC). |
| Q26738691 | Towards tumor immunodiagnostics |
| Q38710450 | Tumor PD-L1 expression is correlated with increased TILs and poor prognosis in penile squamous cell carcinoma |
| Q55518010 | Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers. |
| Q64926812 | Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Pre- and Posttreatment Breast Cancers in the SWOG S0800 Phase II Neoadjuvant Chemotherapy Trial. |
| Q26747792 | Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting |
| Q47560973 | Tumor-associated CD204+ M2 macrophages is an unfavorable prognosticator in uterine cervical adenocarcinoma |
| Q37616487 | Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer. |
| Q55167238 | Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer. |
| Q41964740 | Type Iγ phosphatidylinositol phosphate kinase regulates PD-L1 expression by activating NF-κB. |
| Q47917843 | Type, Frequency, and Spatial Distribution of Immune Cell Infiltrates in CNS Germinomas: Evidence for Inflammatory and Immunosuppressive Mechanisms |
| Q42971341 | Unvalidated antibodies and misleading results |
| Q37739214 | Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer |
| Q28075719 | Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation |
| Q36939402 | Variability in Immunohistochemical Detection of Programmed Death Ligand 1 (PD-L1) in Cancer Tissue Types. |
Search more.